NASDAQ · LEGN
Healthcare · Biotechnology
$22.30
Up+$0.02 (+0.09%)
Updated Oct 30, 2026, 1:51 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LEGN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
LEGN closed at $22.30 after 21 trading sessions, up 15.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $22.55 | $22.955 | $22.04 | $22.30 | 2.37M |
| Oct 28, 2026 | $21.30 | $22.98 | $20.911 | $22.53 | 2.36M |
| Oct 27, 2026 | $20.39 | $21.665 | $19.9082 | $21.56 | 2.12M |
| Oct 26, 2026 | $19.17 | $21.04 | $19.075 | $20.39 | 2.37M |
| Oct 23, 2026 | $18.87 | $19.29 | $18.44 | $19.27 | 979.58K |
| Oct 22, 2026 | $18.42 | $18.97 | $18.40 | $18.90 | 1.2M |
| Oct 21, 2026 | $19.01 | $19.115 | $18.49 | $18.63 | 1.56M |
| Oct 20, 2026 | $18.83 | $19.15 | $18.60 | $19.01 | 1.14M |
| Oct 19, 2026 | $18.55 | $18.915 | $17.995 | $18.65 | 1.89M |
| Oct 16, 2026 | $19.69 | $19.77 | $18.40 | $18.48 | 2.96M |
| Oct 15, 2026 | $19.25 | $19.92 | $18.85 | $19.80 | 1.57M |
| Oct 14, 2026 | $17.94 | $19.7319 | $17.745 | $19.04 | 3.54M |
| Oct 13, 2026 | $17.61 | $18.28 | $17.56 | $17.88 | 2.47M |
| Oct 12, 2026 | $18.40 | $18.49 | $17.69 | $17.80 | 2.63M |
| Oct 9, 2026 | $18.78 | $19.06 | $18.545 | $18.62 | 1.39M |
| Oct 8, 2026 | $18.91 | $18.91 | $18.09 | $18.71 | 2.15M |
| Oct 7, 2026 | $18.725 | $19.235 | $18.58 | $19.12 | 1.57M |
| Oct 6, 2026 | $19.00 | $19.25 | $18.55 | $18.72 | 1.35M |
| Oct 5, 2026 | $18.495 | $18.82 | $17.9153 | $18.775 | 1.76M |
| Oct 2, 2026 | $19.35 | $19.64 | $18.52 | $18.57 | 2.53M |
| Oct 1, 2026 | $19.61 | $19.78 | $19.19 | $19.32 | 2.22M |
The latest Smart Investors Daily articles mentioning LEGN.
Company
Market Activity
Research & News
LEGN research
Company profile and research snapshot.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Barclays | Overweight | — |
| Oct 9, 2026 | JP Morgan | Neutral | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Investing.com -- Morgan Stanley cut German residential property companies Vonovia and LEG to "underweight" from "equal-weight" on Tuesday after Berlin’s three main left-of-centre parties made progress toward a coalition that broadly agreed to expropriate large privately owned housing portfolios.
Yahoo · Oct 15, 2026
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech’s in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in
Benzinga · Oct 13, 2026
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.
Benzinga · Oct 9, 2026
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LEGN.
